Monday, October 02, 2023 10:03:08 PM
X 1. Full ownership of Adderall IR $335 Million
X 2. In house marketing and distribution: Kirkov
X 3. Generic OxyContin- FIRST TO FILE Aug 17, 2023 $720 Million
—4. Full ownership of Adderall XR $ 1.56 Billion
—5. Generic Concerta- $1.2 BILLION
—6. Generic Vyvanse- $5.3 BILLION
X 7. Vigabatrin - approved Commercialized by Pyros $233 Million
—8. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
—9. Patented Unique ADF (w/o naltrexone)-- NDA
—10. Mikah ANDA
—11. Undisclosed
—12. Antimetabolite ANDA- Methotrexate -$600 Million
—13. Undisclosed Antimetabolite ANDA- $42 Million
—14. Prasco/Burel Adderall agreement
—15. Dexcel partnership approval by Israeli health for European distribution
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM